Cargando…

The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by reduced differentiation of myeloid cells and uncontrolled cell proliferation. AML is prone to drug resistance and has a high recurrence rate during treatment with cytarabine-based chemotherapy. Our study aims to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Xiangyu, Zhao, Mengjie, Wu, Zhuo-Xun, Yao, Jingfang, Zhang, Lei, Wang, Jinhong, Hu, Zhenbo, Wei, Liuya, Chen, Zhe-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039182/ https://www.ncbi.nlm.nih.gov/pubmed/35494054 http://dx.doi.org/10.3389/fonc.2022.855570

Ejemplares similares

Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells
por: Zhao, Mengjie, et al.
Publicado: (2022)

The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification
por: Yao, Jingfang, et al.
Publicado: (2022)

Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells
por: Li, Fahui, et al.
Publicado: (2022)

Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients
por: Zhou, Lulu, et al.
Publicado: (2018)

Histone deacetylase 9 deficiency exaggerates uterine M2 macrophage polarization
por: Liu, Yanqin, et al.
Publicado: (2021)

The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer
por: Knoche, Shelby M., et al.
Publicado: (2022)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
por: Weberpals, Johanne I, et al.
Publicado: (2011)

Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling
por: Zhang, Peng, et al.
Publicado: (2015)

Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure
por: Wang, Yao, et al.
Publicado: (2021)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells
por: Tomoyasu, Chihiro, et al.
Publicado: (2019)

Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway
por: Zhang, Wenwen, et al.
Publicado: (2020)

Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells
por: Cui, Yudan, et al.
Publicado: (2021)

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
por: Fredly, Hanne, et al.
Publicado: (2013)

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
por: Gao, Congying, et al.
Publicado: (2023)

Expression of Cytokine mRNA in Leukemic Cells from Adult T Cell Leukemia Patients
por: Kodaka, Taiichi, et al.
Publicado: (1989)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

The PWWP2A Histone Deacetylase Complex Represses Intragenic Spurious Transcription Initiation in mESCs
por: Wei, Guifeng, et al.
Publicado: (2020)

Modulators of histone demethylase JMJD1C selectively target leukemic stem cells
por: Yang, Yong, et al.
Publicado: (2020)

Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
por: Shi, Yingfeng, et al.
Publicado: (2022)

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
por: Ungerstedt, Johanna S.
Publicado: (2018)

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
por: Zhang, Juan, et al.
Publicado: (2021)

Histone deacetylase 8 inhibition prevents the progression of peritoneal fibrosis by counteracting the epithelial-mesenchymal transition and blockade of M2 macrophage polarization
por: Zhou, Xun, et al.
Publicado: (2023)

Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells
por: Menschikowski, Mario, et al.
Publicado: (2012)

ArtinM Mediates Murine T Cell Activation and Induces Cell Death in Jurkat Human Leukemic T Cells
por: da Silva, Thiago Aparecido, et al.
Publicado: (2017)

Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy
por: Ke, Xiangyu, et al.
Publicado: (2021)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination
por: St Germain, Carly, et al.
Publicado: (2010)

Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells
por: Chatterjee, Namita, et al.
Publicado: (2013)

Histone deacetylase 6 regulates cytokinesis and erythrocyte enucleation through deacetylation of formin protein mDia2
por: Li, Xuehui, et al.
Publicado: (2017)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy
por: Adeshakin, Adeleye O., et al.
Publicado: (2022)

Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis
por: Luque-Martin, Rosario, et al.
Publicado: (2019)

Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways
por: Qu, Mei, et al.
Publicado: (2021)

Inhibition of mTOR-Dependent Autophagy Sensitizes Leukemic Cells to Cytarabine-Induced Apoptotic Death
por: Bosnjak, Mihajlo, et al.
Publicado: (2014)

Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
por: Park, Seohyun, et al.
Publicado: (2016)

Short chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway
por: Park, Jeongho, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l6pq2191o8t61uks61t6k9j12p